Anyone been on SGN-LIV1A?

Options
grahaad1
grahaad1 Member Posts: 36

Looking at this for my next treatment. Anyone participate in this trial?

"The data presented at SABCS on SGN-LIV1A demonstrate promising early antitumor activity with a 37 percent partial response rate in patients with triple negative metastatic breast cancer, for which there are no available targeted treatments. We are enrolling additional patients with triple negative metastatic breast cancer in our phase 1 study to optimize the dose and inform the next steps for development of SGN-LIV1A in this population with high unmet need"

Categories